secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2026-06-12T20:06:06+00:00
Accession:  0001193125-26-269387
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics shareholders elect directors, ratify auditor, approve Say-on-Pay at 2026 meeting
--------------------------------------------------------------------------------

- Natasha Hernday and Eric Dobmeier elected as Class II directors; Hernday received 42.85M votes for, Dobmeier 46.28M.
- Ernst & Young ratified as independent auditor for FY2026 with 53.56M votes for, 113k against.
- Advisory vote on named executive officer compensation passed with 42.75M For, 4.57M Against, 46k abstentions.
- Total shares outstanding 60.96M; 53.74M shares represented at the meeting (88% quorum).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526269387/0001193125-26-269387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526269387/janx-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-269387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer